Daiichi Sankyo Europe today reaffirmed its dedication to tackling unmet needs and barriers in cardiovascular care by highlighting treatment disparities and outcomes among different patient groups. This announcement coincides with…
CharmHealth, a leader in healthcare technology solutions, has unveiled the winners of its 2024 Innovation Challenge. Entering its fourth year, the challenge aims to discover groundbreaking ideas poised to transform…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic for the treatment of…
BostonGene, a leader in AI-driven molecular and immune profiling, will showcase its advanced technologies at the 14th World Clinical Biomarkers & CDx Summit 2024, held from September 3 – 6…
Delcath Systems, Inc. (Nasdaq: DCTH), a company specializing in interventional oncology for treating liver cancers, announced the publication of a clinical study in the journal Therapeutic Advances in Medical Oncology.…
Navigator Medicines, a biotech company focused on advancing biologics for immune regulation, announced a $100 million Series A financing and the in-licensing of NAV-240 and an OX40L-targeted portfolio from IMBiologics…
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company dedicated to developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), has…
GE HealthCare (Nasdaq: GEHC) has announced the CE marks for its Vscan Air™ SL wireless handheld ultrasound system, now integrated with Caption AI™ software, which uses artificial intelligence to enable…
Simulations Plus, Inc. (Nasdaq: SLP), a top provider of biosimulation, simulation-enabled performance, intelligence solutions, and medical communications for the biopharma industry, has announced an optimization of its business unit and…
bluebird bio, Inc. (Nasdaq: BLUE) announced on August 20, 2024, that it received notices from Nasdaq stating it is not in compliance with Nasdaq Listing Rule 5250(c)(1). This is due…
Pfizer Inc. and BioNTech SE announced that the U.S. FDA has approved their supplemental Biologics License Application for the Omicron KP.2-adapted COVID-19 vaccine (COMIRNATY®) for individuals aged 12 and older.…
Verint® (NASDAQ: VRNT), known as The CX Automation Company™, has announced that a leading healthcare provider is significantly expanding its deployment of the Verint Interaction Wrap Up Bot, increasing its…